4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
CytomX Therapeutics, Inc. (CTMX) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 69 employees. Its market capitalization is roughly $801 million. In the fiscal year ended 2025-12-31, CTMX reported $76M in revenue and ($17M) in net income.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Interactive charts & full statements → Open the CTMX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $76M | $138M | $101M | $53M |
| Operating Income (EBIT) | ($22M) | $25M | ($6M) | ($101M) |
| Net Income | ($17M) | $32M | ($1M) | ($99M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $10M | $1M | $6M | $19M | $51M |
| Operating Income (EBIT) | ($20M) | ($28M) | ($16M) | ($1M) | $23M |
| Net Income | ($18M) | ($26M) | ($14M) | ($0M) | $24M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $152M | $120M | $202M | $261M | — |
| Total Liabilities | $53M | $121M | $249M | $347M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTMX viewer.
About TickerBase · Data methodology & sources